Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 3/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25427582 | 0.90 | GAA (0.43) | TRPV1HSD17B10MEN1MAPTKMT2A | |
| SCHEMBL17278395 | 0.85 | EPHX2 (0.58) | TRPV1HSD17B10MEN1MAPTKMT2A | |
| SCHEMBL7625860 | 0.80 | CNR1 (0.43) | TRPV1HSD17B10MEN1MAPTKMT2A | |
| SCHEMBL18381322 | 0.79 | SMN1; SMN2 (0.48) | MAPT | |
| SCHEMBL16093045 | 0.78 | FAAH (0.38) | TRPV1HSD17B10MEN1MAPTKMT2A | |
| SCHEMBL16328356 | 0.78 | FAAH (0.42) | TRPV1HSD17B10MEN1MAPTKMT2A | |
| SCHEMBL21210882 | 0.77 | ALDH1A1 (0.43) | — | |
| SCHEMBL21211012 | 0.77 | ALDH1A1 (0.43) | — | |
| SCHEMBL18923937 | 0.76 | FAAH (0.42) | TRPV1HSD17B10MEN1MAPTKMT2A | |
| SCHEMBL15875646 | 0.74 | TBXAS1 (0.56) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100173835-A1 | Peptides for Treatment of Obesity | NOVO NORDISK A/S (DK) | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173835-A1 | Peptides for Treatment of Obesity | MC4R, GIPR, MC3R | TRPV1 255/4885HSD17B10 1788/4885MEN1 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.